Dr. Fanale on Challenges Facing Treatments in T-Cell Lymphoma

Michelle A. Fanale, MD, associate professor, Department of Lymphoma/Myeloma, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, discusses challenges with treatment options for patients with T-cell lymphoma.

The selection of treatments for patients with T-cell lymphoma is a main challenge that is facing this field, states Fanale. When comparing the new agents, they seem to have an overall response rate of 30% to 40% and have complete remission rates between 15% and 20%.

Many of the ongoing clinical trials in this space are attempting to determine which treatment is more suitable for an individual patient through molecular profiling, explains Fanale.